Gefitinib is a targeted cancer therapy used primarily in the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), designed to block specific proteins that drive cancer cell growth. By targeting epidermal growth factor receptor (EGFR) mutations, Gefitinib provides a more personalized approach to treatment, improving outcomes for patients with EGFR-positive NSCLC.
This revolutionary drug is often prescribed as a first-line treatment and offers several advantages, including oral administration, making it more convenient for patients. Its ability to selectively target cancer cells also reduces side effects compared to traditional chemotherapy.
Gefitinib Tablet Manufacturer has significantly improved survival rates and quality of life for many patients. As research progresses, its role continues to expand, highlighting the importance of targeted therapies in modern oncology and offering hope to those battling complex cancers.
